Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a new study from NDM’s Division of Structural Biology, researchers have found out how HIV-1 breaches the cell’s most guarded barrier, revealing the determinants that control the nuclear import of HIV-1.

Human immunodeficiency virus type 1 (HIV-1) has remained one of the most formidable challenges to human health since the first reported case in 1981, causing approximately 42.3 million deaths in total and over a million new infections every year.

Despite advances in treatment, there is still no cure to fully eradicate the virus once infected. A key reason why HIV-1 is so persistent is its ability to insert its genetic material into the DNA of host cells, especially CD4+ T cells and macrophages, creating a lifelong infection. To do this, the virus must deliver its genetic material, protected within a protein shell called the capsid, with other viral proteins named as the viral core, into the cell nucleus through a tightly controlled structure known as the nuclear pore complex (NPC). Exactly how HIV-1 navigates this highly controlled gateway has remained a mystery.

A team of researchers in Professor Peijun Zhang’s lab in the Division of Structural Biology (STRUBI) has achieved a breakthrough in understanding how HIV-1 traverses through the NPC into the nucleus of human cells. Using a combination of state-of-the-art cryo-electron microscopy techniques, the scientists captured nearly 1,500 viral cores in the act of nuclear import, a fleeting and elusive step in HIV-1’s life cycle.

The study, published in Nature Microbiology, establishes a robust cell-permeabilisation system that mimics the conditions of HIV-1 infection on the nuclear import process. This is then followed by the development of an advanced cryo-correlative workflow, combining cryo-CLEM, cryo-FIB milling, and cryo-electron tomography to snapshot HIV-1 as it interacts with the NPC.

The results reveal that successful nuclear entry depends not just on the shape and flexibility of viral core, but also on the NPC’s adaptability and host cell factors like CPSF6. The nuclear pores themselves act as selective gates, favouring smaller and tubular cores and the passage of HIV-1 leads to the expansion and deformation of NPCs. Brittle viral cores fail to enter the pore, while mutants that can’t bind CPSF6 get stuck inside the NPC, unable to proceed into the nucleus. These findings highlight a finely tuned interplay between HIV-1 and the human NPC.

Prof Zhang, Professor of Structural Biology and Wellcome Trust Investigator at STRUBI, said: ‘These insights could have profound implications for antiviral strategies and open new avenues for studying what happens after the virus gets inside the nucleus, especially how it sheds its outer shell and integrates into the host genome. The system and workflow developed in this study also provide a powerful platform for in situ analysis of diverse nuclear processes with broad biological relevance. This work marks a major leap forward in visualising HIV at its most critical stage and understanding how to potentially stop it.’

Read the full paper on the Nature website: https://www.nature.com/articles/s41564-025-02054-z

Similar stories

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

A New Layer of Control for a Decades-Old Leukemia Drug

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led jointly by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

Team ATLAS sets out strategy to investigate cancer avoidance as part of Cancer Grand Challenges

A new position paper from team ATLAS sets out plans to build a cancer antibody atlas to investigate why some people avoid cancer, while others develop disease.

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

New study improves early detection of life threatening infection in children across South and South East Asia

A new study published in Nature Medicine suggests that simple, low-cost tools could help health workers identify children at risk of life-threatening infection earlier, improving access to urgent care in across South and South East Asia.